Kernal Biologics develops onco-selective mRNA therapeutics, engineering the message itself so that it is translated in cancer cells and largely ignored in healthy ones. The pandemic proved mRNA can be manufactured and delivered at scale, but oncology poses a harder problem than vaccination: a therapy that instructs cells to produce a cytotoxic or immune-activating protein must be confined to the tumour, or the toxicity that limits conventional treatment simply reappears in a new form.

Rather than relying on delivery vehicles alone to achieve targeting, Kernal builds selectivity into the construct so that the cancer cell’s own machinery determines whether the payload is expressed. Getting that right would widen the therapeutic window for a class of drugs that is otherwise fast to design and manufacture. Backed since 2021 and funded through a 25 million dollar Series A, this is deep-domain science where value accrues through clinical validation over years rather than through commercial traction. The manufacturing advantages of mRNA mean that a validated construct can move to scale far faster than a conventional biologic.